Fedovapagon

Drug Profile

Fedovapagon

Alternative Names: VA-106483; VA483

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vantia Therapeutics
  • Class Antidiuretics; Small molecules
  • Mechanism of Action Vasopressin V2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Nocturia

Most Recent Events

  • 03 Oct 2017 Vantia Therapeutics announces intention to submit NDA to US FDA and MAA to EMA for Nocturia
  • 03 Oct 2017 Positive top-line safety and efficacy data from the phase II/III trial in Nocturia released by (Vantia Therapeutics)
  • 03 Oct 2017 Vantia Therapeutics plans a second pivotal phase III trial for Nocturia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top